 BeiGene Ltd NASDAQ: BGNE announced an option, collaboration, and license agreement with Novartis AG NYSE: NVS to develop, manufacture, and commercialize BeiGenes ociperlimab in North America, Europe, and Japan. Ociperlimab is currently being investigated in two global Phase 3 trials, the AdvanTIG-301 and AdvanTIG-302 trials, combined with tislelizumab in lung cancer. 